Ivermectin Research
Dr. John Campbell talks with Professor Coleen Aldous
NTKP Note:
This is a remarkable interview about a remarkable substance called Ivermectin discovered by William Campbell and Satoshi Ōmura for which they received the Nobel Prize (2015).
It is a gift to humanity.
I am going to use two Wikipedia quotes from the same article to illustrate the battles and outdated prejudice to Ivermectin’s repurposed use for human Covid-19 treatment. They show why Wikipedia has gained a reputation as such an untrusted source of accurate information.
Quote 1 (This is fair): “Ivermectin - Antiparasite medication
Ivermectin is an antiparasitic drug. After its discovery in 1975, its first uses were in veterinary medicine to prevent and treat heartworm and acariasis. Approved for human use in 1987, it is used to treat infestations including head lice, scabies, river blindness, strongyloidiasis, trichuriasis, ascariasis and lymphatic filariasis.” -Wikipedia
Quote 2 (This is outdated and inaccurate): “Misinformation has been widely spread claiming that ivermectin is beneficial for treating and preventing COVID-19.[23][24] Such claims are not backed by credible scientific evidence.[25][26][27] Multiple major health organizations, including the US Food and Drug Administration,[28] the US Centers for Disease Control and Prevention,[29] the European Medicines Agency,[26] and the World Health Organization have advised that ivermectin is not recommended for the treatment of COVID-19.[26][30] ” -Wikipedia
Dr Jon Campbell discusses Professor Coleen Aldous’s paper on Ivermectin research in which safe and effective use of Ivermectin to save patient lives has been shown.
How prestigious western medical journals refuse to publish Professor Aldous’s paper (Now reviewed and published in top Japanese and Korean journals)
It’s just over an hour long but well well worth it. It should be distributed to all doctors as a lesson in critical thinking
Please share this as widely as possible
YouTube Notes
53,872 views • Apr 13, 2025
With Professor Colleen Aldous Critical appraisal of multidrug therapy in the ambulatory management of patients with COVID-19 and hypoxemia Part II: Causal inference using the Bradford Hill criteria
Eleftherios Gkioulekas, Ph.D.1,*, Peter A. McCullough, M.D., M.P.H.2 and Colleen Aldous, Ph.D.3
PDF URL: https://www.jstage.jst.go.jp/article/antibiotics/78/1/78_35/_pdf/-char/en
We continue the critical appraisal of three published case series of 119 COVID-19 patients with hypoxemia, treated in the United States, Zimbabwe, and Nigeria with similar ivermectin-based multidrug treatments, to assess the available evidence supporting a causal relationship between treatment and reduction in hospitalizations and mortality. A narrative review was conducted to assess the Bradford Hill criteria for a causal association. We used a previously proposed refinement of the Bradford Hill criteria that reorganized them into three categories of direct, mechanistic, and parallel evidence. The efficacy of the two most aggressive ivermectin-based multidrug protocols is supported by the Bradford Hill criteria for temporality, strength of association, biological gradient, biological plausibility, coherence, consistency, and analogy. The causal relation between the treatment of hypoxemic COVID-19 patients using these protocols and the reduction in hospitalizations and mortality is supported as an inference to the best explanation.
Eleftherios Gkioulekas 1,∗ , Peter A. McCullough 2 , and Colleen Aldous 3:
URL for PDF Link: https://faculty.utrgv.edu/eleftherios.gkioulekas/papers/032-c19-ivm-oxygen.pdf
On March 11, 2020, Coronavirus Disease 2019 (COVID-19), the disease caused by the Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2), was declared a pandemic by the World Health Organization (WHO) [1].
Worldwide, 768,187,096 confirmed cases of COVID-19 and 6,945,714 deaths have been reported to the WHO as of June 21 2023, amounting to an average Case Fatality Rate (CFR) of 0.9% [2].
During 2020, while several governments and public health agencies were focused on contagion control and in-hospital patient care, several medical doctors from all around the world innovated and discovered early outpatient multidrug treatments using several repurposed medications in combination [3–15].
In the United States, several independent efforts coalesced into the formulation of a sequenced multidrug protocol [10, Fig. 3] (hereafter, McCullough protocol), which is based on the pathophysiological understanding of COVID-19 as a triphasic illness with three overlapping phases:
(1) viral proliferation;
(2) hyperinflammatory cytokine storm (COVID-19 pneumonia); and
(3) thrombosis.
McCullough’s protocol proposed a combination antiviral therapy for treating the viral proliferation phase, immunomodulators for treating the cytokine storm, and antiplatelet agents and antithrombotics for handling the thrombotic stage, based on risk stratification and how the disease presents in each individual patient. Thus, the McCullough protocol is an algorithmic treatment using sequenced multiple drugs in combination and customized to the individual patient and their response to treatment; no single drug is necessary nor sufficient to achieve treatment efficacy towards reducing hospitalizations and deaths.
A recently published update of the McCullough protocol [16, Fig. 3] introduced some adjustments including virucidal nasal washes and oral gargles [17–24].
A large case series of 869 high-risk patients [25, 26], who were treated using an early version of the McCullough protocol, has been compared against population-level and historical controls [27], showing the existence of efficacy with respect to the reduction of mortality and hospitalizations, which is also resilient with respect to random selection bias, provided that patients are treated early enough within the first 3 to 5 days from the onset of illness. Indeed, an earlier study by Fazio et al.[28] showed that the ideal window of opportunity for initiating an effective early outpatient treatment of COVID-19 to prevent hospitalization is approximately within the first 3 days.
How awful for these amazing scientists that their work is not given the credit it deserves. This needs to be shared far and wide... The truth will out.